Generic GLP-1 drug: FDA approves version of liraglutide, diabetes drug related to Ozempic
The Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug Victoza, which is currently in shortage in the country.
The Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug Victoza, which is currently in shortage in the country.
The agency said it prioritizes review of generic versions of the drugs that are in short supply. Victoza, or liraglutide, has been on the FDA’s shortage list since 2023.
“Generic drugs provide additional treatment options which are generally more affordable for patients,” said Iilun Murphy, FDA’s director of the Office of Generic Drugs.
Hikma’s generic drug first received tentative approval in June. The company did not immediately respond to a Reuters request for comment on the drug’s pricing.
Earlier this year, Teva Pharmaceuticals had launched an authorized generic version of Victoza in the U.S.
Rating: 5